Friend or Foe—Are Benign Lymphadenopathies Really Benign?



 

In recent years, we have witnessed major shifts in our understanding of several entities known as “benign lymphadenopathies.” Recognition of new pathogenetic aspects and their influence on the prognosis has changed our diagnostic and treatment approaches. This presentation focuses on important entities including Castleman disease, IgG4-related disease, and benign T- and B-cell proliferations. The discussion will emphasize the most recent recommendations that encompass the changes in the diagnostic work-up and the clinical significance of the rendered pathologic diagnosis.

Originally presented on February 8, 2023, in Park City, Utah.


Lecture Presenter

Anton Rets, MD, PhD

Anton Rets, MD, PhD

Assistant Professor
University of Utah School of Medicine
Medical Director, Hematopathology
ARUP Laboratories

Dr. Anton Rets is a medical director of hematopathology at ARUP Laboratories and an assistant professor at the University of Utah School of Medicine. Dr. Rets received a doctorate degree in pathology from Perm State Medical Academy/St. Petersburg Academy of Postgraduate Medical Education. He then earned his medical degree and completed a pathology residency at Perm State Medical Academy. He also completed an anatomic and clinical pathology residency at the State University of New York Downstate Medical Center before completing a hematopathology fellowship at the University of Utah School of Medicine. Dr. Rets is board certified in anatomic and clinical pathology and hematopathology. He has received several awards, including the Outstanding Teaching award in clinical pathology, the Excellence in Leadership award, and the Outstanding Academic Performance Federal award. His research interests include red blood cell disorders, nonneoplastic hematology, and digital microscopy.


Objectives

After this presentation, participants will be able to:

  • Discuss the WHO-HAEM5 updates on “tumor-like lesions” of lymphoid tissue
  • Review the most current diagnostic and therapeutic considerations for Castleman disease and IgG4-related disease
  • Propose a practical approach to the diagnosis of key tumor-like lesions

Sponsored by:

University of Utah School of Medicine, Department of Pathology, and ARUP Laboratories